Han Sen Xu

Elpiscience Biopharma Ltd. engages in the development of cutting-edge immunotherapies to fight cancer. Its business scope includes technology research and development, transfer of own technology achievements and provision of related technical advice and technical services of biomedicine and biotechnology; import and export, and wholesale of mechanical equipment, electronic products, instrumentation, and plastic products. The company was founded on September 30, 2017 and is headquartered in Shanghai, China.

Elpiscience Biopharmaceuticals, Inc. is an investment holding company, which engages in the research and development of immuno-oncology therapies. It focuses on the development of clinical-stage drug candidates namely, ES102, ES014, ES104, and ES009. The company was founded by Xiao Hui Ji and Hong Tao Lu in June 2017 and is headquartered in Shanghai, China.